<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<title>An Introduction to Bayesian Designs</title>
<meta name="author" content="CG Wang"/>
<style type="text/css">
.underline { text-decoration: underline; }
</style>
<link rel="stylesheet" href="./reveal.js/dist/reveal.css"/>

<link rel="stylesheet" href="./reveal.js/dist/theme/serif.css" id="theme"/>

<link rel="stylesheet" href="./presentation.css"/>
<link rel="stylesheet" href="./reveal.js/plugin/highlight/zenburn.css"/>
<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
</head>
<body>
<div class="reveal">
<div class="slides">
<section id="sec-title-slide">
<h1 class="title">An Introduction to Bayesian Designs</h1><h2 class="author">CG Wang</h2><p class="date">Created: 2023-07-17 Mon 21:36</p>
</section>
<section>
<section id="slide-orge0b7a02">
<h2 id="orge0b7a02">A Preamble</h2>
<div class="outline-text-2" id="text-orge0b7a02">
</div>
</section>
<section id="slide-org4459e78">
<h3 id="org4459e78">A Recent Nature Reviews Paper</h3>

<div id="org70eada2" class="figure">
<p><img src="./Figures/Bayesian/nature_paper.png" alt="nature_paper.png" height="400px" />
</p>
</div>
</section>
<section id="slide-org02e6cfe">
<h3 id="org02e6cfe">A Recent Paper by FDA Authors</h3>

<div id="org9b91977" class="figure">
<p><img src="./Figures/Bayesian/bayesian_fda_paper.png" alt="bayesian_fda_paper.png" height="500px" />
</p>
</div>
</section>
<section id="slide-orgfbb11a6">
<h3 id="orgfbb11a6">The Pfizer COVID-19 Study</h3>
<ul>
<li>Primary efficacy analysis
<ul>
<li>Based on the Bayesian posterior probability that vaccine efficacy (VE) \(>30\%\)</li>
<li>The success criterion was \(P(\mbox{VE} > 30\%) > 98.6\%\) regardless of the p value</li>
<li>Prior distribution of VE was centered at \(30\%\), which was considered pessimistic</li>
<li>Prior distribution was "minimally informative"</li>

</ul></li>
<li>Interim analysis
<ul>
<li>Four planned</li>
<li>Stop for <i>futility</i> if the probability of meeting the success criteria at
the end of the trial was less than 5%</li>
<li>Stop for <i>efficacy</i> if \(P(\mbox{VE} > 30\%) > 99.5\%\)</li>

</ul></li>
<li>Result
<ul>
<li>\(P(\mbox{VE} > 30\%) > 99.99\%\)</li>

</ul></li>

</ul>
</section>
</section>
<section>
<section id="slide-org811739a">
<h2 id="org811739a">Basic Concepts</h2>
<div class="outline-text-2" id="text-org811739a">
</div>
</section>
<section id="slide-org0efaf42">
<h3 id="org0efaf42">Bayes' Rule (or Bayes' Theorem)</h3>

<div id="org8e9fc96" class="figure">
<p><img src="./Figures/Bayesian/bayes_rule.png" alt="bayes_rule.png" height="400px" />
</p>
</div>

<p>
\[P(A|B) = {P(A \cap B) \over P(B)} = {P(B|A) P(A) \over P(B)}\]
</p>
</section>
<section id="slide-orgb922d07">
<h3 id="orgb922d07">The Bayesian Approach</h3>
<div>
\begin{array}{ccccc}
P(A|B) & \propto & P(B|A) & \times & P(A) \\
\Downarrow &     & \Downarrow &    & \Downarrow \\
\pi(\theta | \mbox{Data}) & \propto &
L(\mbox{Data}| \theta)  & \times & \pi_0(\theta)\\
\Uparrow &     & \Uparrow &    & \Uparrow \\
\mbox{posterior knowledge} & \propto & \mbox{information in data} & \times & \mbox{prior knowledge}\\
\end{array}

</div>
</section>
<section id="slide-orgae4fc1c">
<h3 id="orgae4fc1c">Features of Bayesian Approach</h3>
<ul>
<li>Offers a flexible platform for <i>incorporating prior knowledge</i>
<ul>
<li>Follows learning paradigm</li>

</ul></li>
<li>Expresses the magnitude and variability of a quantity of interest using <i>the
entire distribution</i> rather than a point estimate or confidence interval
<ul>
<li>Inference is straightforward with the distribution</li>
<li>E.g., point estimation, interval estimation, hypothesis testing, model
selection, prediction</li>

</ul></li>
<li>Foundation for decision making in the presence of uncertainty</li>
<li>Enables highly <i>complex and flexible clinical trial designs</i>
<ul>
<li>E.g., adaptive designs, flexible interim monitoring, leveraging historical
or real-world data, population pharmacokinetics and pharmacodynamics, etc.</li>

</ul></li>

</ul>
</section>
<section id="slide-org56b6be7">
<h3 id="org56b6be7">Bayesian or Frequentist?</h3>
<ul>
<li>Frequentist conditions on hypotheses
<ul>
<li>Assuming that the null hypothesis is true, how likely are data we observed
or any unobserved data that are farther from the null hypothesis?</li>
<li>What is the "probability" of observing the data given the null hypothesis, \(P(Data | H_0)\) ?</li>

</ul></li>

</ul>


<div id="orgfcc6c5f" class="figure">
<p><img src="./Figures/Bayesian/frequentist.png" alt="frequentist.png" height="400px" />
</p>
</div>

</section>
<section>
<ul>
<li>Bayesian conditions on data
<ul>
<li>What do we know about the parameters of interest given the data?</li>
<li>Given what we observed, what is the probability that the null hypothesis is
true, \(P(H_0 | Data)\)?</li>

</ul></li>

</ul>


<div id="org0aabc4c" class="figure">
<p><img src="./Figures/Bayesian/bayesian.png" alt="bayesian.png" height="300px" />
</p>
</div>

</section>
<section>
<ul>
<li>Why do we still need frequentist methods in clinical trials?
<ul>
<li>Frequentism is particularly well-suited to the role of regulators</li>
<li>They emphasize procedures that perform well <i>in the long run</i></li>

</ul></li>

</ul>
</section>
</section>
<section>
<section id="slide-org25449f5">
<h2 id="org25449f5">Prior and Prior Elicitation</h2>
<div class="outline-text-2" id="text-org25449f5">
</div>
</section>
<section id="slide-org07f934d">
<h3 id="org07f934d">Prior Knowledge</h3>
<ul>
<li>Sources
<ul>
<li>Preclinical data</li>
<li>Previous study(ies) of the drug of interest or drugs in the same class</li>
<li>Observational outcomes from the target patient population</li>
<li>Expert opinion and/or literature-based estimates</li>

</ul></li>
<li>Goal is not to find the "perfect" knowledge
<ul>
<li>The goal is to incorporate salient features of available scientific knowledge
into the data analysis</li>

</ul></li>

</ul>
</section>
<section id="slide-org1fd4cee">
<h3 id="org1fd4cee">Type of Priors</h3>
<ul>
<li>Based on the amount of information
<ul>
<li>Weakly informative prior</li>
<li>Diffuse or vague prior</li>
<li>Strongly informative prior</li>

</ul></li>
<li>Based on the impact
<ul>
<li>Neutral prior</li>
<li>Enthusiastic prior</li>
<li>Skeptical prior</li>

</ul></li>

</ul>
</section>
<section id="slide-org1db9e69">
<h3 id="org1db9e69">Prior Elicitation</h3>
<ul>
<li>Often difficult for experts to provide direct information on parameters of
statistical models
<ul>
<li>Model parameterization may be unfamiliar</li>
<li>Scale of effect in statistical model may be awkward</li>
<li>e.g., \(\theta \sim \mbox{Beta}(a, b)\)</li>

</ul></li>
<li>In such cases, we elicit information about quantities that are more familiar
to the expert and use that information to induce a prior on the model
parameters
<ul>
<li>Could give a best guess and, perhaps, a wide probability interval for the
quantity of interest</li>

</ul></li>

</ul>
</section>
<section id="slide-orga09b6b3">
<h3 id="orga09b6b3">Prior Elicitation Example</h3>
<ul>
<li>Suppose weight loss for a randomly selected individual under a particular
treatment can be modeled as \(N(\mu, \sigma^2)\)</li>
<li>How would we place a prior on \(\sigma\)?</li>
<li>Since \(\sigma\) is not easy to think about, we could ask questions
about the <i>lower quartile of weight losses</i></li>
<li>This number has 75% of the values above it and 25% below</li>
<li>Lower quartile of a normal distribution is \(\mu − 0.675\sigma\)</li>
<li>If expert’s experience suggests that lower quartile is \(\approx −5\) and
that \(\mu \approx −2\), then a natural guess for \(\sigma\) is
\[\sigma_0 = (−2 + 5)/0.675 = 4.44\]</li>
<li>For \(\sigma^2\), could pick a distribution with median or mode equal to the
best guess, \((4.44)^2\), that is <i>suitably diffuse</i></li>

</ul>
</section>
<section id="slide-orgc5729f3">
<h3 id="orgc5729f3">Sensitivity Analysis</h3>
<ul>
<li>Need to examine whether other reasonable prior distributions lead to
qualitatively similar posterior conclusions</li>
<li>Start with an expert knowledge-based prior (if available) and consider
plausible alternatives to it</li>
<li>Applying Bayesian inferential tools, obtain posterior inferences based on each
prior (expert and alternative) to see affect the choice of prior has on final
inferences</li>
<li>Ideal situation is when there is minimal impact</li>
<li>Report in any analysis when inferences are sensitive to the choice of prior</li>

</ul>
</section>
</section>
<section>
<section id="slide-org9320dac">
<h2 id="org9320dac">Bayesian Designs</h2>
<div class="outline-text-2" id="text-org9320dac">
</div>
</section>
<section id="slide-org7b5e77c">
<h3 id="org7b5e77c">Bayesian Decision-making</h3>
<ul>
<li>A typical <i>Yes-No</i> decision \(\underline{P}(\theta > \underline{R}|Data) > \underline{C}\)
<ul>
<li>A <span class="underline">PRC</span> rule</li>
<li>Based on the posterior probability of the treatment effect(or parameter of
interest), \(P(\theta|Data)\)</li>
<li>Expresses the likelihood of achieving clinically meaningful effect size \(R\)</li>
<li>Utilizes the desired minimum probability \(C\) as the threshold \(C\)</li>

</ul></li>
<li>The choice of \(R\) and \(C\) depend on the disease, the degree of unmet need,
etc
<ul>
<li>A small \(R\) plus large \(C\) combination may give the same decision as a large
\(R\) plus small \(C\)</li>
<li>The choice should <i>achieve the desirable study operating
characteristics</i> such as type I and II error rates</li>
<li>For registrational trials, \(R\) is often set to be \(0\)</li>

</ul></li>

</ul>
</section>
<section id="slide-orgbaf0666">
<h3 id="orgbaf0666">Bayesian Approaches in Clinical Trial Design</h3>
<ul>
<li>"Truly" Bayes
<ul>
<li>Make inferential decisions to maximize expected utility</li>
<li>E.g., Bayesian <i>optimal designs</i> which choose design parameters to minimize
the lost or maximize the gain <i>conditioning on prior knowledge</i></li>

</ul></li>
<li>Calibrated Bayes
<ul>
<li>Uses Bayesian approaches for modeling the study data</li>
<li>Adjusts design parameters to achieve <i>desirable frequentist operating
characteristics</i> (e.g., type I and II error)</li>

</ul></li>

</ul>
</section>
<section id="slide-org6ddb854">
<h3 id="org6ddb854">Bayesian Design Examples</h3>
<div class="outline-text-3" id="text-org6ddb854">
</div>
<ul class="org-ul">
<li><a id="org9fabbc4"></a>Phase I studies<br />
<ul>
<li>Continue reassessment method</li>
<li>Escalation with overdose control</li>
<li>BOIN design</li>
<li>Joint model for efficacy and toxicity</li>

</ul>
</li>
<li><a id="org9c08c3f"></a>Phase II studies<br />
<ul>
<li>Bayesian continuous monitoring</li>
<li>Adaptive randomization and dose allocation</li>
<li>Hierarchical models</li>

</ul>
</li>
<li><a id="org3843025"></a>Phase III studies<br />
<ul>
<li>Phase II/III seamless trials</li>
<li>Adaptive sample size</li>
<li>Futility analyses using predictive probabilities</li>

</ul>
</li>
</ul>
</section>
</section>
<section>
<section id="slide-orgdcf1c74">
<h2 id="orgdcf1c74">Case Studies</h2>
<div class="outline-text-2" id="text-orgdcf1c74">
</div>
</section>
<section id="slide-org058b663">
<h3 id="org058b663">Case I: A Single Arm Study</h3>
<ul>
<li>Consider a phase II single-arm cancer study with a sample size of 20 and 15
responders</li>
<li>What is the response rate?</li>

</ul>
</section>
<section id="slide-orga6b4381">
<h3 id="orga6b4381">Case II: A Phase II POC Study</h3>
<ul>
<li>Consider a phase II two-arm POC study</li>
<li>Experimental arms vs. Cemi+Chemo</li>
<li>pCR difference \(> 15\%\) is considered clinical meaningful</li>
<li>If the posterior probability of pCR difference \(> 15\%\) is \(<20\%\), arm will be
dropped for futility</li>
<li>If posterior probability is pCR difference \(> 15\%\) is \(>80\%\), may further
develop the experimental drug</li>

</ul>
</section>
<section id="slide-orgda0f448">
<h3 id="orgda0f448">Case III: Subgroup Analysis</h3>
<div class="outline-text-3" id="text-orgda0f448">
</div>
<ul class="org-ul">
<li><a id="orgc5bc8ba"></a>Bayesian Hierarchical Models<br />
<div id="org3fe451d" class="figure">
<p><img src="./Figures/Bayesian/bhm.png" alt="bhm.png" height="450px" />
</p>
</div>

</section>
<section>
<ul>
<li>The Bayesian hierarchical model is both natural and flexible for combining
information</li>

</ul>


<div id="org33e8d79" class="figure">
<p><img src="./Figures/Bayesian/bhm_2.png" alt="bhm_2.png" height="350px" />
</p>
</div>
</li>
</ul>
</section>
<section id="slide-org036d7cc">
<h3 id="org036d7cc">Case Study IV: Mixture Prior</h3>
<ul>
<li>There are already existing studies from which we can draw informed priors for
designing a new study</li>
<li>However, we are <i>uncertain that the new study will be similar enough</i> to the
existing studies</li>
<li>Even if they are the same, we don't want the prior knowledge to dominate the
new study</li>

</ul>
</section>
<section>
<ul>
<li>Bayesian solution
<ul>
<li>Consider a robust prior which is a <i>mixture of informative and
non-information priors</i></li>
<li>The mixture prior serves as a prior that discounts the existing knowledge</li>
<li>Example: a robust prior for response rate can be constructed as
\[\pi_0(rate) = 0.7 Beta(1,1) + 0.3 Beta(45, 15),\]
where \(Beta(15, 45)\) is from an existing study
<ul>
<li>The mixing weights \(0.7\) and \(0.3\) are design parameters that will need to
be elicited from experts</li>

</ul></li>

</ul></li>

</ul>
</section>
<section>

<div id="orgd0b6bdb" class="figure">
<p><img src="./Figures/Bayesian/mixture_prior.png" alt="mixture_prior.png" height="350px" />
</p>
</div>
</section>
<section id="slide-org9411589">
<h3 id="org9411589">Case Study V: A Study with a Drop-An-Arm Design</h3>
<ul>
<li>Consider a study with arms
<ul>
<li>A: Control</li>
<li>B: Chemo + Cemi (High Dose)</li>
<li>C: Chemo + Cemi (Low Dose)</li>

</ul></li>
<li>We will not have sufficient data to conclude if Arm B is superior to
Arm C by frequentist hypothesis testing</li>
<li>We would like to select one arm from Arms B and C as early as we can</li>
<li>It will be efficient if we can share information between Arms B and C since
they are similar</li>

</ul>
</section>
<section>
<ul>
<li>Bayesian solution
<ul>
<li>Let \(\alpha_B\) and \(\alpha_C\) be the response rate for arms B and C,
respectively</li>
<li>Model \(\alpha_B\) and \(\alpha_C\) jointly to allow information sharing between
Arms B and C</li>
<li>Assign a prior to \((\alpha_B, \alpha_C)\) such that
<ul>
<li>\(\alpha_C \sim \pi_0(\alpha)\)</li>
<li>\(\alpha_B|\alpha_C\) has mean \(\alpha_C\) with some variance</li>

</ul></li>
<li>Update the posterior distributions of \(\alpha_B\) and
\(\alpha_C\) after every cohort of, say \(5\) patients</li>
<li>Drop arm \(C\) if \(P(\alpha_B > \alpha_C | \mbox{data}) > 0.6\)</li>
<li>Drop arm \(B\) if \(P(\alpha_C > \alpha_B | \mbox{data}) > 0.6\)</li>

</ul></li>

</ul>
</section>
<section id="slide-orgd5ee196">
<h3 id="orgd5ee196">Case Study VI: Leveraging Real-World Data and Real-World Evidence</h3>

<div id="org367f1ea" class="figure">
<p><img src="./Figures/Bayesian/bayes_rwd.png" alt="bayes_rwd.png" height="500px" />
</p>
</div>
</section>
<section id="slide-orgbfa1f55">
<h3 id="orgbfa1f55">Case Study VII: Bayesian Umbrella, Bucket and Platform Trials</h3>

<div id="org44c980a" class="figure">
<p><img src="./Figures/Bayesian/bucket.png" alt="bucket.png" height="500px" />
</p>
</div>
</section>
</section>
<section>
<section id="slide-org3086a00">
<h2 id="org3086a00">Summary</h2>
<div class="outline-text-2" id="text-org3086a00">
</div>
</section>
<section id="slide-orgcb8359f">
<h3 id="orgcb8359f">Why Bayesian?</h3>
<ul>
<li>"Good" reason
<ul>
<li>The study should employ a <i>flexible</i> design to incorporate <i>external
knowledge</i> that is essential for achieving its objectives</li>

</ul></li>
<li>"Not-that-good" reasons
<ul>
<li>We do not have a valid hypothesis to test</li>
<li>We do not have adequate knowledge about the treatment</li>
<li>we lack a suitable criterion for determining the success of the study</li>

</ul></li>

</ul>
</section>
<section id="slide-orgcebd6e1">
<h3 id="orgcebd6e1">Next Session?</h3>
<ul>
<li>Focus on phase I study designs
<ul>
<li>3+3</li>
<li>BOIN</li>

</ul></li>

</ul>
</section>
</section>
</div>
</div>
<script src="./reveal.js/dist/reveal.js"></script>
<script src="./reveal.js/plugin/markdown/markdown.js"></script>
<script src="./reveal.js/plugin/highlight/highlight.js"></script>
<script>
// Full list of configuration options available here:
// https://github.com/hakimel/reveal.js#configuration
Reveal.initialize({

controls: true,
progress: true,
history: false,
center: true,
slideNumber: false,
rollingLinks: false,
keyboard: true,
mouseWheel: false,
fragmentInURL: false,
hashOneBasedIndex: false,
pdfSeparateFragments: true,
overview: true,
margin: 0.10,

transition: 'convex',
transitionSpeed: 'default',

// Plugins with reveal.js 4.x
plugins: [ RevealMarkdown, RevealHighlight ],

// Optional libraries used to extend reveal.js
dependencies: [
]

});
</script>
</body>
</html>
